HEC88473, a novel drug that combines GLP-1 and FGF21 activity, reduced liver fat by up to 47% and HbA1c by 1.1% in patients with fatty liver disease and type 2 diabetes after only 5 weeks of weekly injections.
47% liver fat reduction in 5 weeksThe 30.6 mg dose achieved this relative reduction vs 15% with placebo, measured by MRI-PDFF — a remarkably rapid response
What the researchers found
HEC88473, a GLP-1/FGF21 dual agonist given as weekly subcutaneous injections for 5 weeks, produced dose-proportional reductions in liver fat measured by MRI-PDFF. The best-performing dose (30.6 mg) achieved a 47.21% relative reduction in liver fat (p = 0.0143) versus 15.05% with placebo. Patients with higher baseline fat (PDFF >8%) were more likely to achieve >30% relative reductions.
Blood sugar control also improved significantly: HbA1c dropped by up to 1.10% in the 68.0 mg group versus 0.31% with placebo, along with reductions in fasting and post-meal glucose levels. Lipid profiles improved across dose groups. The drug was generally well tolerated, with GI disorders being the most common adverse event (48.3%), mostly mild to moderate.
Why it matters
MASLD (formerly called NAFLD/NASH) affects roughly 30% of adults globally and has no widely approved pharmacological treatment beyond the recently approved resmetirom. The combination of GLP-1 and FGF21 activity is scientifically compelling because GLP-1 addresses appetite and blood sugar while FGF21 directly targets liver fat metabolism and lipid handling. Getting a 47% liver fat reduction in just 5 weeks is striking — most MASLD trials run 24-52 weeks. This drug's ability to simultaneously improve liver fat, blood sugar, and lipids could make it a single treatment for the cluster of metabolic problems that define metabolic syndrome.
The numbers in context
n=60; liver fat ↓47.21% (30.6mg, p=0.0143) vs ↓15.05% placebo; HbA1c ↓1.10% (68mg) vs ↓0.31% placebo; 48.3% GI adverse events; 5 doses tested; 5-week treatment
How the study worked
Randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase Ib/IIa trial. 60 patients with MASLD and T2DM randomized 10:2 to HEC88473 (5 dose levels: 5.1-68.0 mg) or placebo via weekly subcutaneous injection for 5 weeks. Primary outcomes included liver fat by MRI-PDFF, HbA1c, fasting and postprandial glucose, and lipid profiles. Safety assessed through adverse event monitoring.
Who was studied
60 patients with both metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM)
What this study cannot tell us
This was a small Phase Ib/IIa trial (60 patients total, only 10 per dose group). The 5-week treatment duration is extremely short — longer studies are needed to confirm sustained efficacy and assess safety over months to years. No histological endpoints (liver biopsy) were assessed, which are considered the gold standard for MASLD trials. The 10:2 randomization ratio means only 2 placebo patients per cohort, limiting statistical power for safety comparisons. All patients were from China, so results may not generalize to other populations. The GI adverse event rate of 48.3% warrants monitoring at longer durations.
How to read the evidence
Rated moderate because this is a well-designed randomized, double-blind, placebo-controlled human trial published in the Journal of Hepatology (top-tier). However, it's an early-phase trial (Ib/IIa) with only 60 patients, a very short 5-week duration, no histological endpoints, and small placebo groups per cohort.
When this study was published
Published in 2025, this represents the cutting edge of metabolic drug development. HEC88473 is in early clinical development, and larger Phase II/III trials would be expected if the company advances the program.
The bigger picture
The metabolic drug landscape is rapidly evolving beyond single-target GLP-1 agonists toward multi-pathway approaches. Tirzepatide (GLP-1/GIP) and retatrutide (GLP-1/GIP/glucagon) have shown that combining pathways produces greater effects. HEC88473 takes a different approach by pairing GLP-1 with FGF21 — specifically targeting liver fat metabolism. This positions it competitively for the massive MASLD market, where liver-specific efficacy is the key requirement. Published in the Journal of Hepatology (the field's top journal), these results from a Chinese pharmaceutical development program add to a wave of metabolic drugs emerging from China's biotech sector.
Questions still open
- Will the dramatic liver fat reductions seen at 5 weeks translate into improvements in liver fibrosis and inflammation on biopsy in longer trials?
- How does HEC88473 compare head-to-head with tirzepatide or resmetirom for liver fat reduction?
- Does the FGF21 component provide liver-specific benefits beyond what GLP-1 alone achieves, and would this justify the more complex molecule?
Common questions
What's different about combining GLP-1 with FGF21 versus other combinations?
Is a 47% reduction in liver fat clinically meaningful?
Read the original research
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
Journal of hepatology, 82(6), 967-978
Citation
Xiang, Lin; Wang, Guixia; Zhuang, Yulei; Luo, Lin; Yan, Jiangyu; Zhang, Hong; Li, Xiaojiao; Xie, Can; He, Qingwei; Peng, Yuyu; Chen, Hong; Li, Qianqian; Li, Xiaoping; Guo, Linfeng; Lv, Guoyue; Ding, Yanhua. (2025). Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.. Journal of hepatology, 82(6), 967-978. https://doi.org/10.1016/j.jhep.2024.12.006